title: Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia.
abstract: BACKGROUND
  Hereditary motor and sensory neuropathy type Ia (HMSN Ia) is known as a primarily demyelinating peripheral nerve disease. Evidence is accumulating that axonal involvement determines the course of the disease process.
  
  
  METHODS
  Fifty-one patients were investigated. Physical disability and impairments were scored. Nerve conduction velocities (NCVs) were used as indirect measures for myelination status and compound muscle/sensory nerve action potential (CMAP/SNAP) amplitudes served as indirect measures for axonal function.
  
  
  RESULTS
  Median age was 39 years (range 6-69). Muscle weakness and sensory dysfunction was more severe in the legs than in the arms and distally more than proximally. However, more than 40% of the patients had proximal muscle weakness in the legs. Three point grip was used as representative of combined distal arm muscle groups. CMAP amplitude was the most important independent variable in a multiple linear regression model (forward selection) to explain the relation between three point grip strength and four different features, i. e., CMAP amplitude of the abductor pollicis brevis, median nerve MNCV, gender, and duration of signs and symptoms. The severity of axonal dysfunction was nerve length-dependent and was related to the myelination status. The mild physical disability due to both muscle weakness and sensory dysfunction was also related to axonal dysfunction.
  
  
  CONCLUSIONS
  In HMSN Ia, clinical disease severity at the impairment and disability levels is related to the severity of axonal dysfunction. Our data support the hypothesis that the myelination status is one of the factors that determine the extent of axonal dysfunction later in life. Proximal weakness of the legs is encountered in a considerable proportion of our patients.
authors.affiliation: Department of Neurology and Clinical Neurophysiology, H2-222, Academic Medical Centre, University of Amsterdam, PO Box 22700, 1100, DE Amsterdam, The Netherlands. c.verhamme@amc.uva.nl
authors.forename: Camiel
authors.initials: C
authors.lastname: Verhamme
authors.forename: Ivo N
authors.initials: IN
authors.lastname: van Schaik
authors.forename: Johannes H T M
authors.initials: JH
authors.lastname: Koelman
authors.forename: Rob J
authors.initials: RJ
authors.lastname: de Haan
authors.forename: Marinus
authors.initials: M
authors.lastname: Vermeulen
authors.forename: Marianne
authors.initials: M
authors.lastname: de Visser
mesh_terms: D000200:Action Potentials; D000293:Adolescent; D000328:Adult; D000368:Aged; D001369:Axons; D002607:Charcot-Marie-Tooth Disease / Q000175:diagnosis / Q000503:physiopathology*; D002648:Child; D006233:Persons with Disabilities; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D012720:Severity of Illness Index